TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05769634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stereoelectroencephalography
Description: Three computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation will be completed. The first asks patients to attend to their heartbeat to manipulate interoceptive attention. The second asks patients to judge affective pictures to manipulate states of arousals. The third engages patients in a probabilistic reward-learning task, or gambling task, and anticipate the outcomes of risky decision-making. A final task guides patients to slow their breathing to 6 breaths per minute.
Study: NCT06230302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey postbiotics derived from kefir lactic acid bacteria
Description: Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
Study: NCT05248334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection
Description: The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV
Description: Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
Study: NCT04251728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation
Description: Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Exercise
Description: The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
Study: NCT06326684

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effects of placebo will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The effects of suvorexant dose 1 will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The effects of suvorexant dose 2 will be determined.
Study: NCT05721677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate based topical skin adhesive
Description: Tissue adhesive on CVL exit-site
Study: NCT05615636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO
Study: NCT05657457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: intra-arterial tenecteplase
Study: NCT06230302

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
Study: NCT06077916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin is reconstituted and administered according to standard prescription indications in 250 mL saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution
Description: placebo consisting of saline solution 250 mL is administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: placebo consisting of saline solution 250 mL is administered
Study: NCT06210451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water-based gel
Description: Insertion of the speculum during ET will be performed using 5 gr of water-based, sterile gel
Study: NCT06174974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
Study: NCT04935801

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: LD vehicle-GNP
Description: Two intradermal injections in the upper arm spaced 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LD PepGNP-Dengue
Description: Two intradermal injections in the upper arm spaced 21 days apart

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: HD vehicle-GNP
Description: Two intradermal injections in the upper arm spaced 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD PepGNP-Dengue
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study: NCT05738837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-EAAA Sexual Assault Resistance Education Program immediately
Description: Adapted from the EAAA program created for university women, A-EAAA is designed for teen girls of all sexual identities and experience levels. It focuses on resisting sexual assault (SA) committed by male acquaintances with 4, 3-hour units: Unit 1(Assess) strengthens girls' ability to detect risk in contexts involving male acquaintances and helps develop strategies to reduce it. Unit 2(Acknowledge) helps girls explore ways to overcome their own emotional barriers preventing them from acknowledging risk and employing effective resistance strategies with males they know. Unit 3(Act) provides evidence on effectiveness of various resistance strategies and teaches verbal and physical self-defense focused on common acquaintance SA situations. Unit 4 (Relationships\&Sexuality) is an adaptation of Our Whole Lives curriculum and aims to increase girls' comfort talking about sex/sexuality and identify their sexual values/desires and explore possibilities for sexual practices beyond intercourse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care + A-EAAA at 6 months
Description: Participants assigned to the waitlist control group will immediately receive a brief educational session on sexual assault that represents the current 'standard of care' at Canadian high schools (often presented by local Sexual Assault Centres or Public Health nurses). This 30-min session will involve a brief 15 - 20-minute presentation on sexual consent, respect in relationships, and sexual assault (e.g., definitions, prevalence statistics). This will be conducted by a well-trained and knowledgeable Research Assistant. Following the presentation, participants will be invited to take and read brochures provided on sexual assault, and to ask questions about the content of the presentation and brochures. At 6-months, participants will be scheduled to receive A-EAAA.
Study: NCT06010550

Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: Brain magnetic resonance imaging
Study: NCT04817033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intraoperative dexmedetomidine sedation
Description: Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intraoperative dexmedetomidine sedation
Description: Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
Study: NCT05922527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined regenerative technique
Description: Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement
Study: NCT04817033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intraoperative midazolam sedation
Description: Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intraoperative midazolam sedation
Description: Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
Study: NCT04702399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEL GROUP
Description: Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
Study: NCT05436652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62
Description: 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62
Description: 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62 matched placebo
Description: Inactive tablets identical in appearance to SPI-62 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62 matched placebo
Description: Inactive tablets identical in appearance to SPI-62 tablets
Study: NCT05362695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
Study: NCT05328388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycomato
Description: Lycomato sof gels
Study: NCT05939791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518
Description: The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
Study: NCT05436652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 10mg
Description: Standard of care prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 10mg
Description: Standard of care prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional prednisolone
Description: Over encapsulated prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional prednisolone matched placebo
Description: Inactive capsules identical in appearance to over encapsulated prednisolone
Study: NCT05869279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARCIK-CD19
Description: allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
Study: NCT05344690

Intervention type: GENETIC
Intervention: SLMAP and EPO genetic polymorphism
Description: Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms

Intervention type: GENETIC
Intervention: SLMAP and EPO genetic polymorphism
Description: Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Study: NCT06140576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindilimab
Description: Sindilimab, 200mg, Intravenous，every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8mg, 12mg, 16mg everyday
Study: NCT05197153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Half dose of MVC-COV1901
Description: Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose of MVC-COV1901
Description: Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Half dose of mRNA-1273
Description: Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
Study: NCT06538519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement using lateral approach
Description: In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total hip replacement using anterior approach
Description: the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gait analysis at 6wks, 3 months and 18 months
Description: gait analysis done in the gait lab at the mentioned postoperative periods

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gait analysis at 6wks, 3 months and 18 months
Description: gait analysis done in the gait lab at the mentioned postoperative periods
Study: NCT05454254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualised muscle strengthening exercise training protocol.
Description: Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
Study: NCT05896696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeShape One
Description: Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
Study: NCT06008106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tunlametinib
Description: 12mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
Description: according to investigators' suggestion
Study: NCT06442293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: A dietary supplement containing beet root extract, arginine and citrulline

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: A dietary supplement containing beet root extract, arginine and citrulline

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: A dietary supplement containing beet root extract, arginine and citrulline

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo supplement that is similar in appearance to treatment 1
Study: NCT05540418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lavender oil inhalation
Description: Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
Study: NCT06399341

Intervention type: DEVICE
Intervention: Papilocare vaginal gel
Description: Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)